# Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

> **NCT00708903** · PHASE1 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** neratinib
- **OTHER:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT00708903
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2012-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00708903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00708903, "Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00708903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*